Skip to search formSkip to main contentSkip to account menu

Luspatercept

A soluble, recombinant fusion protein composed of a modified form of the extracellular domain of human activin receptor type IIb (ActRIIb) and linked… 
National Institutes of Health

Related topics

Related topics

1 relation

Narrower (1)

ACE-536

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Luspatercept to treat β-thalassemia.
Recently, after years of research often characterized by disappointments and frustrations, finally a new drug impacting on… 
Review
2019
Review
2019
Myelodysplastic syndrome Transforming growth factor ( TGF )-β pathway as a therapeutic target in lower risk myelodysplastic syndromes
The transforming growth factor (TGF)-β superfamily comprises more than 30 soluble growth factors that play a central role in… 
2019
2019
Novel therapies in low- and high-risk myelodysplastic syndrome
ABSTRACT Introduction: Myelodysplastic syndromes (MDS) comprise a heterogeneous group of myeloid neoplasms with diverse clinical… 
2018
2018
The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) Transfusions
Introduction: β-thalassemia is an inherited hemoglobinopathy associated with an erythroid maturation defect characterized by… 
2017
2017
Antibody-based strategies for the detection of Luspatercept (ACE-536) in human serum.
Luspatercept (ACE-536, ACVR2B-Fc), a fusion protein consisting of the extracellular domain of ActRIIB receptor and the Fc-part of… 
2016
2016
Luspatercept Increases Hemoglobin, Decreases Transfusion Burden and Improves Iron Overload in Adults with Beta-Thalassemia
Background.Luspatercept (ACE-536) is a modified activin receptor type IIB fusion protein that promotes late-stage erythroid… 
2016
2016
Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS): Long-Term Results from Phase 2 PACE-MDS Study
![Graphic][1] Background: Management of anemia is a common therapeutic challenge in patients with MDS. Luspatercept (ACE-536… 
2015
2015
Luspatercept Treatment Leads to Long Term Increases in Hemoglobin and Reductions in Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results…
Background: Luspatercept is a fusion protein (modified activin receptor IIB-IgG Fc) being investigated for the treatment of… 
2015
2015
Luspatercept (ACE-536) Reduces Disease Burden, Including Anemia, Iron Overload, and Leg Ulcers, in Adults with Beta-Thalassemia: Results from a Phase 2 Study
![Graphic][1] Background. Luspatercept is a fusion protein (modified activin receptor IIB-IgG Fc) being investigated for the… 
2015
2015
Biomarkers of Ineffective Erythropoiesis Predict Response to Luspatercept in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Final Results from the Phase 2 PACE-MDS Study
Background: Luspatercept is a fusion protein (modified activin receptor IIB-IgG Fc) being investigated for the treatment of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)